Erythropoiesis' Stimulating Factors (ESAs) are among the top ten therapeutic groups with the highest pharmaceutical expenditure in Greece. OBJECTIVES: To explore the penetration of ESAs in the Greek pharmaceutical market and differences in pricing levels between originals and biosimilars. METHODS: Data derived from the IKA-ETAM Social Security Fund, covering almost 50% of insured population. Consumption of ESAs (epoetin alfa, darbepoetin alfa, epoetin beta, methoxy polyethylene glycol epoetin beta, epoetin zeta) was collected from the Central & Peripheral Pharmacy, dispensing high value medicines for serious diseases on outpatient basis covering almost 70% geographical area of Greece. Consumption of epoetins was recorded from 2008 to 2010, classified per strength (IU/mcg), separated in originals and biosimilars. The average price per 1000IU of each category was also estimated for the respective years based on NHS hospital prices. RESULTS: ESAs consumption in 2008 and 2009 was approximately the same (26 & 27% respectively) while decreasing by 4% reaching 23% in 2010. A 13,8% decrease was also observed in IKA-ETAM total pharmaceutical expenditure in 2010. ESAs expenditure in 2008, was €41,4 million corresponding to 99% market share (MSH) of originals epoetins, leaving only 1% MSH in biosimilar epoetin zeta launched in that year. In 2009 ESAs expenditure reached €43 million, with 94% and 6% MSH for original and biosimilar ESAs respectively. In 2010 ESAs expenditure was almost halved (€22million), due to price cuts and stricter control of prescriptions. Specifically, the MSH of originals reached 81% and biosimilars 19% respectively. In the reported years prices of biosimilars were slightly different from that of originals, however as of 2011 higher price differences are observed, favoring the use of biosimilars. CONCLUSIONS: Biosimilars penetration in Greece is similar with EU, 6% and 6,64% in 2009 respectively, presenting an increasing rate in 2010. Under the economic recession Greece is experiencing, biosimilars seem to be a cost saving option.
OBJECTIVES: On-demand treatment for haemophilia patients with inhibitors is burdensome to patients and practitioners. Newer bypassing agents with shortened bleed resolution time resulting in fewer infusions, may impact costs and patient quality of life (QoL). The study objective was to model the lifetime costs and healthrelated QoL outcomes associated with bypassing agents, recombinant activated Factor VIIa and plasma-derived activated prothrombin complex concentrate (rF-VIIa, pd-aPCC) in Germany, and investigate the impact of faster bleeding resolution of a new rFVIIa analogue. METHODS: Assuming a German payer perspective, this literature-based model tracks a hypothetical cohort of severe haemophilia patients with inhibitors over their lifetime. A semi-Markov model was used to simulate patient movement through health states at 3-month intervals. Modeled outcomes include lifetime direct treatment costs, cost per bleeding episode, life-years, and quality-adjusted life years (QALYs) across a continuum of home and inpatient care. One-way sensitivity analyses were performed on all model variables and two-way sensitivity analyses on key variables. RESULTS: Using base-case assumptions from the literature, rFVIIa was associated with measurable lifetime cost savings compared with pd-aPCC (€ 2,962,833 vs. € 4,664,971, respectively) and reduced total cost per bleed compared with pd-aPCC (€ 17,614 vs. € 19,435, respectively) . Reducing the number of rFVIIa infusions per bleed from 2.3 to 1.5 resulted in incremental cost savings of € 248,033, while 20% utility improvement in rFVIIa conferred a 3.14 additional QALY gain. Sensitivity analyses confirmed the robustness of base case findings. CONCLUSIONS: This exploratory model is a valuable tool for physicians to assess the impact of current treatment patterns over a patient's lifetime and to potentially identify optimal practice patterns. Availability of bypassing agents with improved efficacy profiles could result in significant improvement of patient care. Barcelona, Spain, 9 GlaxoSmithKline, Brentford, UK, 10 GlaxoSmithKline, Uxbridge, UK, 11 GlaxoSmithKline, Marly-le-Roi, France OBJECTIVES: Evaluate rate of flares in adult SLE patients with active antinuclear autoantibody positive SLE disease and estimate the incremental direct costs of flare management. METHODS: A multi-centre retrospective chart review study extracting patient characteristics, disease activity and severity, and medical resource utilization in 5 European countries (France, Germany, UK, Italy and Spain). Patients were stratified by disease severity at inclusion visit (50% severe) and followed-up for 2 years. Severe disease defined as having at least one major domain actively involved (renal, neurological, cardiovascular or respiratory) and requiring Ͼ7.5 mg/day of corticosteroids and/or immunosuppressants. A modification of SELENA-SLEDAI Flare Index collected retrospectively was used for identifying mild/ moderate and severe flares. Unadjusted mean costs associated with management of flares were assessed. Health care perspective and country specific data was used for resources and costs analysis. RESULTS: The total sample included 427 SLE patients (212 severe, 215 non-severe), mean age: 43.4 years, female: 90.5%. Total mean number of flares over the study period was 2.29 compared to 1.83 (pϽ0.001) for severe and non-severe patients respectively. Mean number of mild/moderate flares was 0.87 compared to 1.32 (pϽ0.001), while mean number of severe flares was 1.42 compared to 0.52 (pϽ0.001) for severe and non-severe patients, respectively. The mean two year costs for patients experiencing at least one flare over study period was €9607 compared to €3910 (pϽ0.001) without flares. Exploratory flare analysis showed a mean 2 year increase in costs of €4525 (pϽ0.01) per severe flare (no statistical significance for mild/moderate flares). CONCLUSIONS: Severe patients experience both a higher number of flares and more severe flares compared to non-severe patients. Patients experiencing at least one flare over the study period are 2.5 times more costly than patients without flares; the presence of severe flares in SLE patients has a significant impact on the healthcare system.
PSY17 RETROSPECTIVE CHART REVIEW STUDY OF THE COST OF CARE OF SYSTEMTIC LUPUS ERYTHEMATOUSUS (SLE) IN FIVE EUROPEAN COUNTRIES

PSY18 RESOURCE CONSUMPTION EVALUATION FOR KETOPROPHENE, KETOROLAC, PARECOXIB AND TENOXICAM AT ORTHOPEDIC SURGERY POST-OPERATION IN BRAZILIAN PATIENTS FROM PRIVATE PAYERS PERSPECTIVE
Fujii RK 1 , Mould JF 2 , Lanzara G 3 1 Pfizer Pharmaceutics inc., São Paulo, São Paulo, Brazil, 2 Pfizer, Inc., New York, NY, USA, 3 Pfizer Parmaceutics Inc., São Paulo, São Paulo, Brazil OBJECTIVES: The rational use of resources is essential for granting sustainability at any healthcare system. This study aims to evaluate the best anti-inflamatory medication regarding costs consumption from private payer's perspective. METHODS: 400 medical charts from 3 private hospitals in Curitiba city were accessed retrospectively from November to April (2010) and selected based on the use of intravenous ketoprophene (200mg/day), ketorolac (60mg/day), parecoxib (40mg/day) or tenoxicam (40mg/day) at the immediate post-operative adult patients from orthopedic surgeries period and based on the existence of hospital's billing information.
One hundred twenty-one cases were recruited. Resource use considered were antacid, antiemetic and analgesic drugs, infusion equipment, medication costs (factory list prices) and labor costs were estimated from the amount of minutes per day to administering the medications. The minimum monthly wage for a nurse according to the Brazilian nurses union was considered (593.75 USD). Costs are expressed in 2010 USD. RESULTS: Parecoxib presented the least daily resource consuming profile with an average of 33.52 USD compared to 68.27; 67.16 and 75.05 USD for ketoprophene, ketorolac and tenoxicam. Daily average expenditure on the consumption of antacid analgesic and antiemetic medications was 6.00, 10.19, 12.43 and 8.50 USD for parecoxib, ketoprophene, ketorolac and tenoxicam (PC/KP/KL/TM) respectively. Total time expenditure per day and costs were 12.5 min (4.96 USD), 26.75 min (10.59 USD), 27.43min (10.85 USD) and 25.20 min (9.97 USD) for PC/KP/ KL/TM respectively. Daily savings by using parecoxib were found in 2.53, 13.04 and 7.16 USD against KP/KL/TM, respectively. CONCLUSIONS: Parecoxib was found to be the less costly alternative to the hospital by rationing the number of administrations per day, the use of antacid, analgesic and antiemetic medications and the total labor time costs for administering the medications. 
PSY19 ECONOMIC COSTS OF CHEMOTHERAPY-INDUCED FEBRILE NEUTROPENIA AMONG PATIENTS WITH NON-HODGKIN'S LYMPHOMA IN EUROPEAN CLINICAL PRACTICE
OBJECTIVES: Cost of chemotherapy-induced febrile neutropenia (FN) in the United
States has been reported to be substantial. Little is known about the cost of FN in other countries or about costs of follow-on care and subsequent FN events. METHODS: Data were obtained from an observational study of supportive care in patients with non-Hodgkin's lymphoma (NHL) receiving CHOP-14 or CHOP-21 chemotherapy (Ϯrituximab) predominantly across Europe. FN was defined as single oral temperature of Ն38.3°C or temperature of Ն38.0°C for Ն1 hour, and neutrophil count of Ͻ0.5x109/L or Ͻ1.0x109/L and predicted to fall below 0.5x109/L. Patients developing FN in a given cycle ("FN patients"), starting with the first cycle, were matched (1:1, without replacement) on age, tumor stage, chemotherapy, and other factors to those not developing FN in that cycle ("comparison patients"), irrespective of FN experience in subsequent cycles. FN-related healthcare utilization and costs (estimated from UK National Health Service perspective [2010]) were tallied for patients from the match cycle through the last chemotherapy cycle ("follow-up"). RESULTS: Eighteen percent of patients (331/1829) in the observational study experienced a total of 479 FN events, the majority (77%) of which required inpatient care. A total of 295 FN patients were matched to comparison patients for these analyses; baseline characteristics were similar between groups. During follow-up, FN patients averaged 1.44 (95%CI 1.34-1.56) FN events and comparison patients averaged 0.15 (0.10-0.21) FN events, and corresponding mean number of FN-related hospital days was 6.21 (5.28-7.17) and 0.63 (0.30-1.02). Mean total cost was £5744 (£4893-£6664) higher for FN patients than comparison patients, with 71% of the difference attributable to care in the index cycle (£4051 [£3633-£4485]) and 29% attributable to care in post-index cycles (£1693 [£917-£2447]). CONCLUSIONS: Cost of chemotherapy-induced FN among NHL patients in European clinical practice is substantial, with a sizable percentage attributable to follow-on care and subsequent FN events.
PSY20 THE ANNUAL DIRECT MEDICAL COST OF SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) PATIENTS AND COSTS DRIVERS (LUCIE STUDY): FRENCH RESULTS
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